Blood pressure lowering treatment for those with SBP > 160 mmHg and total CVD risk < 30%
Cost-effectiveness — what published models estimate per unit of health impact
$/DALY
$85–176
WHO-CHOICE modeled
GiveWell
—
no GiveWell model
CE sources
3
Tier A · 69 studies
Source agreement
comparable
within 2.5×
Cost-effectiveness
Estimates are sourced in their native units and shown for comparison, not as literal costs. Sources use different frameworks — see each card for what it represents and how it was derived.
Modeled benchmarks ($/DALY)Tier A · standardized benchmark
WHO-CHOICE estimates are modeled at 50% population coverage, compared against the null set (no intervention) under generalized cost-effectiveness analysis. View WHO-CHOICE methodology →
$/DALY sources within 2.5x - treat as comparable, not ranked.
Modeled regional estimates — not realized delivery costs.
Published study estimates ($/DALY)Tier B · context only
Tufts GHCEA · 68 studies, varied methods — explore the spread, not a single number.
Health-system
cost-saving
median · n=42
Societal
cost-saving
median · n=26
Filter the cohort
cost-savingmedian of 68 studies · IQR $-9,706–$86 · 46 cost-saving
Published study estimates ($/DALY)Tier B · context only
DCP3 (2013 reference)$2850median · 1 study
Varied methods — not directly comparable.
Data completeness: not assessed (no country selected) · Evidence confidence: not assessed (no country selected)
Looking for supply/market data for Blood pressure lowering treatment for those with SBP > 160 mmHg and total CVD risk < 30%? Select a country above, then open its intelligence page.